Contemporary management of patients with T1a and T1b prostate cancer

Research output: Contribution to journalArticle

Abstract

Purpose of Review: Incidental prostate cancer (PCa) - T1a to T1b - still represents a non-negligible clinical entity requiring good decision-making skills to correctly manage patients, most of whom may have insignificant tumours. The aim of the current review is to summarize the available evidence-based information that may be helpful in daily clinical practice. Recent Findings: Although having major clinical implications, the current TNM staging system for incidental PCa has not been re-evaluated for 20 years. Recently, many reports questioned the accuracy of T1a-T1b classification and strengthened the fact that the decisions to offer further treatment in cases of incidental cancer should be based upon the estimated probability of clinical progression compared to the relative risk of therapy and potential benefit to survival. The use of prostate-specific antigen (PSA) levels before and after transurethral resection of the prostate (TURP) and Gleason score at diagnosis may help in estimating the need for further therapy. Summary: Active surveillance should be recommended for well differentiated incidental cancers in patients with limited life expectancy and low PSA levels after TURP or, alternatively, in patients who are uncomfortable with potential treatment-related complications. In patients with a longer life expectancy - especially for poorly differentiated tumours - radical prostatectomy should be considered. PSA levels before and after TURP increase the accuracy in estimating the need for active management. Further studies focusing on biologic and clinical markers of progression are mandatory to identify those patients who require active treatment after incidental PCa diagnosis.

Original languageEnglish
Pages (from-to)252-256
Number of pages5
JournalCurrent Opinion in Urology
Volume21
Issue number3
DOIs
Publication statusPublished - May 2011

Fingerprint

Prostatic Neoplasms
Transurethral Resection of Prostate
Prostate-Specific Antigen
Life Expectancy
Neoplasms
Biomarkers
Therapeutics
Neoplasm Grading
Neoplasm Staging
Prostatectomy
Decision Making
Survival

Keywords

  • benign prostatic hyperplasia
  • prostate cancer
  • radical prostatectomy
  • T1a
  • T1b
  • transurethral resection

ASJC Scopus subject areas

  • Urology

Cite this

Contemporary management of patients with T1a and T1b prostate cancer. / Capitanio, Umberto.

In: Current Opinion in Urology, Vol. 21, No. 3, 05.2011, p. 252-256.

Research output: Contribution to journalArticle

@article{8fb220e94674447a87ecf7cd227374f5,
title = "Contemporary management of patients with T1a and T1b prostate cancer",
abstract = "Purpose of Review: Incidental prostate cancer (PCa) - T1a to T1b - still represents a non-negligible clinical entity requiring good decision-making skills to correctly manage patients, most of whom may have insignificant tumours. The aim of the current review is to summarize the available evidence-based information that may be helpful in daily clinical practice. Recent Findings: Although having major clinical implications, the current TNM staging system for incidental PCa has not been re-evaluated for 20 years. Recently, many reports questioned the accuracy of T1a-T1b classification and strengthened the fact that the decisions to offer further treatment in cases of incidental cancer should be based upon the estimated probability of clinical progression compared to the relative risk of therapy and potential benefit to survival. The use of prostate-specific antigen (PSA) levels before and after transurethral resection of the prostate (TURP) and Gleason score at diagnosis may help in estimating the need for further therapy. Summary: Active surveillance should be recommended for well differentiated incidental cancers in patients with limited life expectancy and low PSA levels after TURP or, alternatively, in patients who are uncomfortable with potential treatment-related complications. In patients with a longer life expectancy - especially for poorly differentiated tumours - radical prostatectomy should be considered. PSA levels before and after TURP increase the accuracy in estimating the need for active management. Further studies focusing on biologic and clinical markers of progression are mandatory to identify those patients who require active treatment after incidental PCa diagnosis.",
keywords = "benign prostatic hyperplasia, prostate cancer, radical prostatectomy, T1a, T1b, transurethral resection",
author = "Umberto Capitanio",
year = "2011",
month = "5",
doi = "10.1097/MOU.0b013e328344e4ad",
language = "English",
volume = "21",
pages = "252--256",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Contemporary management of patients with T1a and T1b prostate cancer

AU - Capitanio, Umberto

PY - 2011/5

Y1 - 2011/5

N2 - Purpose of Review: Incidental prostate cancer (PCa) - T1a to T1b - still represents a non-negligible clinical entity requiring good decision-making skills to correctly manage patients, most of whom may have insignificant tumours. The aim of the current review is to summarize the available evidence-based information that may be helpful in daily clinical practice. Recent Findings: Although having major clinical implications, the current TNM staging system for incidental PCa has not been re-evaluated for 20 years. Recently, many reports questioned the accuracy of T1a-T1b classification and strengthened the fact that the decisions to offer further treatment in cases of incidental cancer should be based upon the estimated probability of clinical progression compared to the relative risk of therapy and potential benefit to survival. The use of prostate-specific antigen (PSA) levels before and after transurethral resection of the prostate (TURP) and Gleason score at diagnosis may help in estimating the need for further therapy. Summary: Active surveillance should be recommended for well differentiated incidental cancers in patients with limited life expectancy and low PSA levels after TURP or, alternatively, in patients who are uncomfortable with potential treatment-related complications. In patients with a longer life expectancy - especially for poorly differentiated tumours - radical prostatectomy should be considered. PSA levels before and after TURP increase the accuracy in estimating the need for active management. Further studies focusing on biologic and clinical markers of progression are mandatory to identify those patients who require active treatment after incidental PCa diagnosis.

AB - Purpose of Review: Incidental prostate cancer (PCa) - T1a to T1b - still represents a non-negligible clinical entity requiring good decision-making skills to correctly manage patients, most of whom may have insignificant tumours. The aim of the current review is to summarize the available evidence-based information that may be helpful in daily clinical practice. Recent Findings: Although having major clinical implications, the current TNM staging system for incidental PCa has not been re-evaluated for 20 years. Recently, many reports questioned the accuracy of T1a-T1b classification and strengthened the fact that the decisions to offer further treatment in cases of incidental cancer should be based upon the estimated probability of clinical progression compared to the relative risk of therapy and potential benefit to survival. The use of prostate-specific antigen (PSA) levels before and after transurethral resection of the prostate (TURP) and Gleason score at diagnosis may help in estimating the need for further therapy. Summary: Active surveillance should be recommended for well differentiated incidental cancers in patients with limited life expectancy and low PSA levels after TURP or, alternatively, in patients who are uncomfortable with potential treatment-related complications. In patients with a longer life expectancy - especially for poorly differentiated tumours - radical prostatectomy should be considered. PSA levels before and after TURP increase the accuracy in estimating the need for active management. Further studies focusing on biologic and clinical markers of progression are mandatory to identify those patients who require active treatment after incidental PCa diagnosis.

KW - benign prostatic hyperplasia

KW - prostate cancer

KW - radical prostatectomy

KW - T1a

KW - T1b

KW - transurethral resection

UR - http://www.scopus.com/inward/record.url?scp=79955051621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955051621&partnerID=8YFLogxK

U2 - 10.1097/MOU.0b013e328344e4ad

DO - 10.1097/MOU.0b013e328344e4ad

M3 - Article

C2 - 21358335

AN - SCOPUS:79955051621

VL - 21

SP - 252

EP - 256

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 3

ER -